Michael W Sill

Michael W Sill

UNVERIFIED PROFILE

Are you Michael W Sill?   Register this Author

Register author
Michael W Sill

Michael W Sill

Publications by authors named "Michael W Sill"

Are you Michael W Sill?   Register this Author

63Publications

948Reads

19Profile Views

Paclitaxel and Pazopanib in Ovarian Cancer-Reply.

JAMA Oncol 2018 Sep;4(9):1299

NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.1712DOI Listing
September 2018

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

J Clin Oncol 2016 07 23;34(19):2279-86. Epub 2016 May 23.

Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph's Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of California Irvine Medical Center, Orange; Jai Balkissoon, Pharmaceutical Product Development International, South San Francisco, CA; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; Jeanne M. Schilder, Indiana University Medical Center, Indianapolis, IN; and Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.8153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962710PMC
July 2016

Improved survival with bevacizumab in advanced cervical cancer.

N Engl J Med 2014 Feb;370(8):734-43

From the University of California, Irvine, Medical Center, Orange (K.S.T.); Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo (M.W.S., H.H.); Mayo Clinic, Rochester, MN (H.J.L.); Massachusetts General Hospital, Boston (R.T.P.); M.D. Anderson Cancer Center, Houston (L.M.R.); University of Oklahoma, Oklahoma City (L.M.L.); Vall d'Hebron University Hospital, Barcelona (A.O.); University of Cincinnati College of Medicine-Women's Cancer Center at Kettering, Kettering, OH (T.J.R.); Memorial Sloan-Kettering Cancer Center, New York (M.M.L.); Indiana University School of Medicine, Indianapolis (H.E.M.); and the University of Arizona Cancer Center and Creighton University at St. Joseph's Hospital and Medical Center, Phoenix (B.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1309748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094PMC
February 2014

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

Gynecol Oncol 2012 Dec 7;127(3):456-61. Epub 2012 Sep 7.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.08.030DOI Listing
December 2012

A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

Gynecol Oncol 2012 Nov 14;127(2):356-61. Epub 2012 Jul 14.

Department of Obstetrics and Gynecology, Gynecologic Oncology Section, University of Oklahoma, Oklahoma City, OK 73104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.07.095DOI Listing
November 2012

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Gynecol Oncol 2012 Sep 24;126(3):424-7. Epub 2012 May 24.

Dept. of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.05.024DOI Listing
September 2012

A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.

Clin Trials 2012 Aug 18;9(4):385-95. Epub 2012 Jul 18.

Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774512450101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598604PMC
August 2012

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

Gynecol Oncol 2012 Mar 1;124(3):563-8. Epub 2011 Dec 1.

Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.11.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278517PMC
March 2012

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.

Gynecol Oncol 2011 Mar 7;120(3):459-63. Epub 2010 Dec 7.

Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a Member of Catholic Healthcare West, 500 W. Thomas Road, Suite 800, Phoenix, AZ 85013, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.11.012DOI Listing
March 2011

A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

Int J Gynecol Cancer 2009 Jul;19(5):929-33

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/IGC.0b013e3181a83467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722934PMC
July 2009

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

J Clin Oncol 2009 Mar 12;27(7):1069-74. Epub 2009 Jan 12.

University of California, Irvine Medical Center, Bldg 56, Room 262, 101 The City Dr, Orange, CA 92868. USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.18.9043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667811PMC
March 2009

Drop-the-Losers Design: Binomial Case.

Comput Stat Data Anal 2009 Jan;53(3):586-595

The GOG Statistical and Data Center - Roswell Park Cancer Institute - Elm & Carlton Streets - and - The Dept. of Biostatistics - University at Buffalo, Buffalo NY USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.csda.2008.07.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654329PMC
January 2009

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

Gynecol Oncol 2008 Dec 30;111(3):455-60. Epub 2008 Sep 30.

Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2008.07.049DOI Listing
December 2008

Female adolescents' perceptions of male partners' pregnancy desire.

J Midwifery Womens Health 2008 Jul-Aug;53(4):338-44

State University of New York College at Brockport School of Nursing, 350 New Campus Dr., Brockport, NY 14420-2988, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmwh.2007.12.002DOI Listing
November 2008

Differences in pregnancy desire among pregnant female adolescents at a state-funded family planning clinic.

J Midwifery Womens Health 2008 Mar-Apr;53(2):130-7

State University of New York College at Brockport, School of Nursing, 350 New Campus Dr., Brockport, NY 14420-2988, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S152695230700388
Publisher Site
http://dx.doi.org/10.1016/j.jmwh.2007.09.005DOI Listing
March 2008

Differences in contraceptive choice among female adolescents at a state-funded family planning clinic.

J Midwifery Womens Health 2008 Jan-Feb;53(1):45-52

School of Nursing at SUNY at Brockport, Brockport, NY 14420-2988, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S152695230700286
Publisher Site
http://dx.doi.org/10.1016/j.jmwh.2007.07.010DOI Listing
January 2008

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

J Clin Oncol 2007 Nov;25(33):5165-71

University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2007.11.5345
Publisher Site
http://dx.doi.org/10.1200/JCO.2007.11.5345DOI Listing
November 2007

A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

Gynecol Oncol 2007 Sep 27;106(3):596-603. Epub 2007 Jun 27.

University of Oklahoma, Department of Gynecologic Oncology, Health Sciences Center, OB/GYN, Oklahoma City, OK 73190, and Department of Reproductive Medicine, University Hospitals of Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2007.05.013DOI Listing
September 2007

Drop-the-losers design: normal case.

Biom J 2005 Jun;47(3):257-68; discussion 269-81

Department of Statistics, University of Pittsburgh, 2701 Cathedral of Learning, Pittsburgh, PA 15260, USA.

View Article

Download full-text PDF

Source
June 2005